Proteon Therapeutics

In June 2017, Deerfield led funding for Proteon Therapeutics Inc. Proteon is developing first-in-class therapeutics to address the medical needs of patients with kidney and vascular diseases. Deerfield originally invested in Proteon in 2014 because of the substantial unmet medical need and confidence in the management team and technology.

Proteon recently announced results from the Phase 3 PATENCY-1 trial and in the subsequent interactions with the FDA it was granted Breakthrough Therapy Designation.